TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21494994

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 16
Study: 19025527

Group type: EXPERIMENTAL
Intervention: 50 mg/kg i.v. magnesium sulphate in 100 ml of 0.9% normal saline
Number of subjects: 83

Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 50 mg/kg i.v. magnesium sulphate
Number of subjects: 83
Study: 17157115

Group type: EXPERIMENTAL
Intervention: Paracetamol/tramadol (PIT) 325 mg/37.5 mg
Number of subjects: 119

Group type: COMPARATOR
Intervention: Tramadol (T) 50 mg
Number of subjects: 119
Study: 12684211

Group type: EXPERIMENTAL
Intervention: Duodenal fat infusion (triglyceride emulsion, 2.8 kcal/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Duodenal fat infusion with lipase inhibition (120 mg tetrahydrolipstatin)
Number of subjects: 16
Study: 11014323

Group type: EXPERIMENTAL
Intervention: Telmisartan 1-160 mg oral single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 10-160 mg intravenous single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 320 mg oral once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 20 and 120 mg oral once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 10, 20, 40, 80, 120, and 160 mg oral once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 40, 80, or 120 mg oral once daily for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 9190129

Group type: EXPERIMENTAL
Intervention: Low intensity general training program (< 50% of heart rate reserve) for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 22
Study: 8185741

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + Lidocaine 1%
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + Mepivacaine 1%
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + Prilocaine 1%
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + Etidocaine 1%
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (Control)
Number of subjects: 76
Study: 3590805

Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (2 g of prednisolone-hemisuccinate every 6 hours for 48 hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29340809

Group type: EXPERIMENTAL
Intervention: Intraincisional ropivacaine 0.2% (3 ml)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Intrapertioneal ropivacaine 0.2% (20 ml)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Normal saline (control group, n=86)
Number of subjects: 294
Study: 25042022

Group type: EXPERIMENTAL
Intervention: Environmental exposure to cigarette smoke (group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No environmental exposure to cigarette smoke (group 2)
Number of subjects: 39
Study: 22324058

Group type: EXPERIMENTAL
Intervention: Whole-body vibration + exercise
Number of subjects: 77

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 77
Study: 20541986

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral support exercise
Number of subjects: 134

Group type: COMPARATOR
Intervention: Typical introductory methods exercise
Number of subjects: 134
Study: 18689718

Group type: EXPERIMENTAL
Intervention: Nisin (6 microg/mL) applied to the nipple and mammary areola for 2 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (similar preparation devoid of nisin)
Number of subjects: 8
Study: 16708816

Group type: EXPERIMENTAL
Intervention: Harnal (0.2 mg/d)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Proscar (5 mg/d)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 222
Study: 12778355

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy according to AML-BFM 93 protocol
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Stem-cell transplantation in first remission
Number of subjects: 471
Study: 10388332

Group type: EXPERIMENTAL
Intervention: Food for Heart Program (nutrition counseling for public health nurses)
Number of subjects: 468
Study: 7733839

Group type: EXPERIMENTAL
Intervention: Levorotatory form of 5-hydroxytryptophan
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2252527

Group type: EXPERIMENTAL
Intervention: prednisone (15 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: indomethacin (100 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 6994638

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 90
Study: 31775065

Group type: EXPERIMENTAL
Intervention: #Tamojunto program
Number of subjects: 3298

Group type: COMPARATOR
Intervention: Baseline risk factors (sociodemographic characteristics, school experiences, social variables)
Number of subjects: 3298
Study: 31344077

Group type: EXPERIMENTAL
Intervention: 9 different simulation sessions over 1 year
Number of subjects: 48

Group type: COMPARATOR
Intervention: 3 simulation sessions (initial, intermediate after 6 months, final after 1 year)
Number of subjects: 48
Study: 28504569

Group type: EXPERIMENTAL
Intervention: Blended essential oil (1:1:1 ratio of L. angustifolia, Salvia sclarea, and Origanum majorana)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Acupressure massage
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lavender essential oil (Lavandula angustifolia)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 132
Study: 26288888

Group type: EXPERIMENTAL
Intervention: Wearable camera system
Number of subjects: 9
Study: 23443360

Group type: EXPERIMENTAL
Intervention: THC administration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 21
Study: 21075015

Group type: EXPERIMENTAL
Intervention: R0 resection at MSKCC (91 patients)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: R0 resection at FALP (33 patients)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: R0 resection at YCU (36 patients)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Patients treated at FALP
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Patients treated at YCU
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Patients treated at MSKCC and YCU
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 261
Study: 19705105

Group type: EXPERIMENTAL
Intervention: Ketotifen (sedating antihistamine)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epinastine (nonsedating antihistamine)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17894263

Group type: EXPERIMENTAL
Intervention: Multicomponent health promotion program
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 266
Study: 15052246

Group type: EXPERIMENTAL
Intervention: Modified QGS software used in patients with angina pectoris (AP)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Modified QGS software used in patients with old myocardial infarction (MI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 81
Study: 11712038

Group type: EXPERIMENTAL
Intervention: Topical aspirin/dichloromethane solution
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9131458

Group type: EXPERIMENTAL
Intervention: PMK‐OPV
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vero‐OPV
Number of subjects: 21
Study: 7924704

Group type: EXPERIMENTAL
Intervention: Ileoanal reservoir procedure in patients over the age of 50 years (Group I)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ileoanal reservoir procedure in patients under the age of 50 years (Group II)
Number of subjects: 72
Study: 3344578

Group type: EXPERIMENTAL
Intervention: Rotation of the puncture needle by 90 degrees
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional lumbar puncture
Number of subjects: 20
Study: 30323393

Group type: EXPERIMENTAL
Intervention: Standardized patients dressed in moulage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Picture-based paper cases
Number of subjects: 0
Study: 27789188

Group type: EXPERIMENTAL
Intervention: 15 mg AMG 747
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 40 mg AMG 747
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 5 mg AMG 747
Number of subjects: 232
Study: 25955224

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (20 μg/kg/d)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (200 μg/d)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combined estrogens and oral contraceptive pills (30 μg of ethinyl estradiol plus 150 μg of desogestrel) and 4 mg/d of estradiol valerate
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonprimed cycles
Number of subjects: 66
Study: 23104720

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab-based chemotherapy (ATBC)
Number of subjects: 276

Group type: COMPARATOR
Intervention: No treatment (ATBC-)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 276

Group type: COMPARATOR
Intervention: Trastuzumab alone
Number of subjects: 276
Study: 21430611

Group type: EXPERIMENTAL
Intervention: Kinesio Taping plus exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Kinesio Taping alone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 39
Study: 18478463

Group type: EXPERIMENTAL
Intervention: Intracolonic drainage (biofragmentable anastomosis ring and condom)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Protective ileostomy
Number of subjects: 119
Study: 17140167

Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14572567

Group type: EXPERIMENTAL
Intervention: 10-Fr bipolar electrocoagulation catheter
Number of subjects: 77

Group type: COMPARATOR
Intervention: 7-Fr bipolar electrocoagulation catheter
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (10-Fr and 7-Fr)
Number of subjects: 77
Study: 10771457

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8835044

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1425625

Group type: EXPERIMENTAL
Intervention: ondansetron 1 mg
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 580

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 580
Study: 6372428

Group type: EXPERIMENTAL
Intervention: Complement group (balanced protein-calorie beverage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplement group (high-protein beverage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (routine vitamin and mineral tablets)
Number of subjects: 0
Study: 31846643

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation followed by esophagectomy
Number of subjects: 7691

Group type: EXPERIMENTAL
Intervention: Positive surgical margins
Number of subjects: 7691

Group type: EXPERIMENTAL
Intervention: Facility surgical volume
Number of subjects: 7691

Group type: EXPERIMENTAL
Intervention: Readmission within 30 days
Number of subjects: 7691

Group type: EXPERIMENTAL
Intervention: Minimally-invasive surgery converted to open
Number of subjects: 7691

Group type: EXPERIMENTAL
Intervention: Age 69 and older
Number of subjects: 7691

Group type: EXPERIMENTAL
Intervention: Esophagectomy more than 45 days from completion of chemoradiation
Number of subjects: 7691
Study: 30067578

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 77
Study: 26702788

Group type: EXPERIMENTAL
Intervention: Electronic Vapour Product (EVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicorette(®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Cigarette (CC)
Number of subjects: 0
Study: 24499763

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation
Number of subjects: 73

Group type: COMPARATOR
Intervention: No mechanical bowel preparation
Number of subjects: 73
Study: 23029839

Group type: EXPERIMENTAL
Intervention: Regional airway nerve blocks (whole airway block including bilateral superior laryngeal nerve block, bilateral glossopharyngeal block, and recurrent laryngeal nerve block)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 100
Study: 20102879

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (p-PCI)
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: Full-dose tenecteplase before PCI (f-PCI)
Number of subjects: 1037
Study: 17350556

Group type: EXPERIMENTAL
Intervention: 2-sided appeals
Number of subjects: 263

Group type: COMPARATOR
Intervention: 1-sided appeals
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Causal arguments
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Authoritative arguments
Number of subjects: 263
Study: 16333795

Group type: EXPERIMENTAL
Intervention: Continuous anticoagulation therapy (INR 2.0 - 3.0) in patients with AF and LA thrombi
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group with equivalent anticoagulation regimen (no LA thrombi)
Number of subjects: 32
Study: 12668861

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (specifically abciximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thienopyridines and glycoprotein (GP) IIb/IIIa inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9809953

Group type: EXPERIMENTAL
Intervention: Clonidine (8 microg/kg infused over 1 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum (PNO)
Number of subjects: 20
Study: 7649753

Group type: EXPERIMENTAL
Intervention: Generic discharge screens indicating absence of documentation of discharge planning
Number of subjects: 20136

Group type: EXPERIMENTAL
Intervention: Generic discharge screens indicating elevated temperature
Number of subjects: 20136

Group type: EXPERIMENTAL
Intervention: Generic discharge screens indicating abnormal pulse
Number of subjects: 20136

Group type: EXPERIMENTAL
Intervention: Generic discharge screens indicating unaddressed abnormal test results at discharge
Number of subjects: 20136

Group type: COMPARATOR
Intervention: Generic discharge screens indicating abnormal blood pressure
Number of subjects: 20136

Group type: COMPARATOR
Intervention: Generic discharge screens indicating IV fluids or drugs
Number of subjects: 20136

Group type: COMPARATOR
Intervention: Generic discharge screens indicating wound drainage before discharge
Number of subjects: 20136
Study: 2664523

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31005964

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation for 6 months
Number of subjects: 1673
Study: 29382477

Group type: EXPERIMENTAL
Intervention: 1 day preparation with PEG 3350 (4 g/kg/day) + bisacodyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 days preparation with PEG 3350 (2 g/kg/day) + bisacodyl
Number of subjects: 0
Study: 25557052

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 7
Study: 22784101

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22011917

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol (group P)
Number of subjects: 100
Study: 18690586

Group type: EXPERIMENTAL
Intervention: Motivational intervention (3 telephone calls at intervals of 2 months)
Number of subjects: 175
Study: 16825685

Group type: EXPERIMENTAL
Intervention: Choline-deficient diet for up to 42 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control diet (recommended adequate intake of choline) for 10 days
Number of subjects: 51
Study: 14633553

Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard management (control)
Number of subjects: 34
Study: 11141242

Group type: EXPERIMENTAL
Intervention: RTV/SQV
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RTV/SQV/d4T
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AZT/3TC/abacavir/nevirapine/indinavir
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26
Study: 9364884

Group type: EXPERIMENTAL
Intervention: Nebulisation of Salbutamol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nebulisation of Ipratropium bromide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Normal saline nebulisation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Humidified oxygen without nebulisation
Number of subjects: 120
Study: 1337206

Group type: EXPERIMENTAL
Intervention: diethyldithiocarbamate
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study: 2882771

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 6
Study: 30326711

Group type: EXPERIMENTAL
Intervention: e-book intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 65
Study: 25611183

Group type: EXPERIMENTAL
Intervention: Autologous serum drops
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional artificial tears
Number of subjects: 30
Study: 24548289

Group type: EXPERIMENTAL
Intervention: Low-flatulogenic test diet (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Balanced control diet (Mediterranean type) (n = 15)
Number of subjects: 30
Study: 23090524

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone and 800 micrograms buccal misoprostol
Number of subjects: 729
Study: 20216098

Group type: EXPERIMENTAL
Intervention: Untreated food allergy patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with food allergy and celiac disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 18594529

Group type: EXPERIMENTAL
Intervention: VAPEC-B+G-CSF
Number of subjects: 80

Group type: COMPARATOR
Intervention: VAPEC-B
Number of subjects: 80
Study: 16144532

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study: 12043955

Group type: EXPERIMENTAL
Intervention: Solution-based intranasal triamcinolone acetonide formulation (Tri-Nasal) at doses of 100, 200, and 400 microg over 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aqueous suspension-based triamcinolone acetonide formulation (Nasacort AQ) at doses of 110, 220, and 440 microg
Number of subjects: 0
Study: 10421591

Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg PO) for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg PO)
Number of subjects: 20
Study: 7547842

Group type: EXPERIMENTAL
Intervention: [15N]yoghurt
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: [15N]milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: [15N]milk and [15N]yoghurt
Number of subjects: 16
Study: 2291597

Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 47

Group type: COMPARATOR
Intervention: Metopimazine
Number of subjects: 47
Study: 7303757

Group type: EXPERIMENTAL
Intervention: Encorton and Imuran
Number of subjects: 36

Group type: COMPARATOR
Intervention: Encorton
Number of subjects: 36
Study: 31182181

Group type: EXPERIMENTAL
Intervention: Low glycaemic index, low insulin index (LGI-LII) meal
Number of subjects: 15
Study: 27832514

Group type: EXPERIMENTAL
Intervention: Prophylaxis with BAY 81-8973
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-demand treatment with BAY 81-8973
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 81-8973
Number of subjects: 0
Study: 25890060

Group type: EXPERIMENTAL
Intervention: Action group (children created an action implementation intention)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control groups (none, coping, both)
Number of subjects: 400
Study: 23053709

Group type: EXPERIMENTAL
Intervention: Two-layer technique, consisting of a first layer of GIC with a flowable consistency (powder/liquid ratio 1:2) and a second layer of a regular consistency
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional technique, one-layer GIC (powder/liquid ratio 1:1)
Number of subjects: 208
Study: 21226681

Group type: EXPERIMENTAL
Intervention: WHR of 0.80 or greater with a BMI of 20.0 to 24.9 kg/m²
Number of subjects: 7163

Group type: EXPERIMENTAL
Intervention: WHR less than 0.80 and a BMI of 20.0 to 24.9 kg/m²
Number of subjects: 7163

Group type: EXPERIMENTAL
Intervention: Underweight women (BMI < 20.0 kg/m²) with a WHR less than 0.80
Number of subjects: 7163

Group type: EXPERIMENTAL
Intervention: Normal-weight to obese women (BMI 20.0-29.9 kg/m²) with central adiposity (WHR ≥ 0.80)
Number of subjects: 7163
Study: 17868404

Group type: EXPERIMENTAL
Intervention: Phospo-soda buffered saline (Fleet)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sodium picosulphate/magnesium citrate (Picoprep)
Number of subjects: 73
Study: 16857842

Group type: EXPERIMENTAL
Intervention: High Botanical Diversity Diet (HBD)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Low Botanical Diversity Diet (LBD)
Number of subjects: 106
Study: 15043519

Group type: EXPERIMENTAL
Intervention: Oral branched chain amino acids
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no nutritional supplement)
Number of subjects: 84
Study: 11764826

Group type: EXPERIMENTAL
Intervention: MD15 Oral Irrigator plus manual brushing
Number of subjects: 64

Group type: COMPARATOR
Intervention: Manual brushing alone
Number of subjects: 64